|
Volumn 108, Issue 2, 2001, Pages 184-190
|
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
a b c d d e d |
Author keywords
Allergy; Anti IgE; Asthma; IgE; Monoclonal antibody; Omalizumab; rhuMAb E25
|
Indexed keywords
BECLOMETASONE DIPROPIONATE;
CORTICOSTEROID;
IMMUNOGLOBULIN E;
IMMUNOGLOBULIN E ANTIBODY;
OMALIZUMAB;
PLACEBO;
UNCLASSIFIED DRUG;
ADOLESCENT;
ADULT;
AGED;
ALLERGIC ASTHMA;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORTICOSTEROID THERAPY;
DISEASE EXACERBATION;
DOUBLE BLIND PROCEDURE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FEMALE;
HUMAN;
IMMUNOGLOBULIN BLOOD LEVEL;
LUNG FUNCTION;
MAJOR CLINICAL STUDY;
MALE;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SCHOOL CHILD;
SIDE EFFECT;
|
EID: 0034907372
PISSN: 00916749
EISSN: None
Source Type: Journal
DOI: 10.1067/mai.2001.117880 Document Type: Article |
Times cited : (1184)
|
References (16)
|